1-20 of 322 results for subject:NHS
Librarians' tools
- Search time
- 0.309 seconds
- Solr query time
- 0.013 seconds
- Search query
- subject:NHS
- We searched for
- subject_t:NHS OR subject_t:"National health service" OR subject_ses:92154
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government what plans they have to review the operation of the NHS COVID-19 app.
To ask Her Majesty's Government what plans they have to review the operation of the NHS COVID-19 app.
The NHS COVID-19 app is kept under close review and is continually being refined and enhanced to ensure it can continue to break chains of transmission. Research from academics and bodies such as The Alan Turing Institute and The University of Oxford have shown that the app continues to work effectively, and user research and feedback are continually considered and incorporated into app releases. Constant evaluation is conducted to ensure the app can continue to support present and future requirements.
To ask Her Majesty's Government whether they will provide the information set out in figure 16 on page 55 of the NHS Resolution annual report and accounts 2020/21 in respect of clinical negligence cases only for the year 2020/21.
To ask Her Majesty's Government whether they will provide the information set out in figure 16 on page 55 of the NHS Resolution annual report and accounts 2020/21 in respect of clinical negligence cases only for the year 2020/21.
The information requested is shown in the following table.
Settlement type | Total number of clinical negligence claims | Number of claims settled with damages | Number of claims settled with No damages | Percentage of all claims settled, with damages | Percentage of all claims settled, no damages |
No proceedings | 8,941 | 4,568 | 4,373 | 37.94% | 36.32% |
Proceedings | 3,066 | 2,478 | 588 | 20.58% | 4.88% |
Trial | 34 | 10 | 24 | 0.08% | 0.2% |
To ask Her Majesty's Government what steps they will take to ensure that public interest in the NHS is protected when private companies receiving NHS contracts already hold seats on Integrated Care System Boards, giving them influence on NHS decision-making.
To ask Her Majesty's Government what steps they will take to ensure that public interest in the NHS is protected when private companies receiving NHS contracts already hold seats on Integrated Care System Boards, giving them influence on NHS decision-making.
Integrated care boards (ICBs) will be National Health Service bodies, bringing in representatives from a range of other bodies including NHS commissioners and providers. The Board will, as a minimum, include a Chair, Chief Executive and representatives from NHS trusts, general practice and local authorities.
Local areas will have the flexibility to determine any further representation on their board. This would be subject to local agreement and approval by NHS England. We do not expect independent providers to have seats on the ICB.
To ask Her Majesty's Government how many people contacted the fast track ‘VIP lane’ for emergency procurement contracts to offer (1) personal protective equipment, and (2) COVID-19 testing equipment or services; and of this number, how many were awarded contracts.
To ask Her Majesty's Government how many people contacted the fast track ‘VIP lane’ for emergency procurement contracts to offer (1) personal protective equipment, and (2) COVID-19 testing equipment or services; and of this number, how many were awarded contracts.
The Department’s buying unit received offers of personal protective equipment (PPE) from approximately 16,000 companies and individuals commonly referred to as the ‘priority’ channel. Of the suppliers assessed through this channel, 47 of 493 obtained contracts.
There was no formal ‘priority’ channel to assess offers of testing kits or services.
To ask Her Majesty's Government how many people have been told to isolate through the NHS Track and Trace app only to (1) show no symptoms, and (2) not need hospitalisation.
To ask Her Majesty's Government how many people have been told to isolate through the NHS Track and Trace app only to (1) show no symptoms, and (2) not need hospitalisation.
The NHS COVID-19 app cannot be used to identify users, whether they showed symptoms or were hospitalised.
To ask Her Majesty's Government what assessment they have made of the accuracy of the NHS COVID-19 contact tracing app in identifying close contacts with people who test positive for the virus.
To ask Her Majesty's Government what assessment they have made of the accuracy of the NHS COVID-19 contact tracing app in identifying close contacts with people who test positive for the virus.
The app uses Bluetooth Low Energy to understand the distance over time between people who have downloaded the app. If someone tests positive for COVID-19, the app’s risk-scoring algorithm uses this data, along with the infectiousness of the individual testing positive, to make calculations about the risk of transmission and who should receive an alert. If a notification to self-isolate is received, the user’s device has been in close proximity to the device of someone who has recently tested positive. For its ability to judge proximity, the app achieves ‘excellent’ performance by scientific standards.
Prior to the launch of the app it was tested in a range of environments, in order to evaluate its effectiveness at accurately measuring distance. The app has also been modelled in simulations involving hundreds of thousands of scenarios. The app performed as expected and we are confident that it can accurately detect distance in different settings. As Apple and Google develop aspects of the underlying contact tracing technology, they have also conducted their own tests related to accuracy.
To ask Her Majesty's Government what assessment they have made of the effect on patient outcomes of the steps being taken by NHS providers to improve such outcomes.
To ask Her Majesty's Government what assessment they have made of the effect on patient outcomes of the steps being taken by NHS providers to improve such outcomes.
We have made no specific assessment.
To ask Her Majesty's Government what process will be followed for Northern Ireland in circumstances where the Medicines and Healthcare products Regulatory Agency approves a licence for a medicine but such approval has not been given by the European Medicines Agency.
To ask Her Majesty's Government what process will be followed for Northern Ireland in circumstances where the Medicines and Healthcare products Regulatory Agency approves a licence for a medicine but such approval has not been given by the European Medicines Agency.
We are committed to maintaining parity of access to medicines across the United Kingdom. In circumstances where the approval dates for products in Great Britain and Northern Ireland differ, doctors can prescribe medicines outside of the label in areas of unmet medical need. The General Medical Council provides clear recommendations to physicians on prescribing medicines which they consider is in the patient’s best interest but may not carry the specific indication. We continue to work with colleagues in Europe to ensure that approval for medicines in Great Britain and Northern Ireland are aligned in the future.
To ask Her Majesty's Government whether they intend to publish a consultation on fixed recovery costs for clinical negligence claims; and if so, when.
To ask Her Majesty's Government whether they intend to publish a consultation on fixed recovery costs for clinical negligence claims; and if so, when.
We are developing proposals to introduce fixed recoverable costs for clinical negligence claims under the value of £25,000. We plan to consult on these measures in due course.
To ask Her Majesty's Government what assessment they have made of (1) the number of NHS staff who have refused a COVID-19 vaccination, and (2) the impact such refusal has made to the spread of COVID-19 in NHS facilities; whether vaccine refusal amounts to gross misconduct; and if so, what...
To ask Her Majesty's Government what assessment they have made of (1) the number of NHS staff who have refused a COVID-19 vaccination, and (2) the impact such refusal has made to the spread of COVID-19 in NHS facilities; whether vaccine refusal amounts to gross misconduct; and if so, what...
Information on the number of National Health Service staff who have refused a COVID-19 vaccination is not held centrally. We encourage all National Health Service staff to take up the offer of the vaccine, to help protect themselves and others.
For staff who decline the vaccine, employers should consider how best to ensure those staff members and patients are safe. This could include measures such as making sure the appropriate personal protective equipment is being used, that fit testing has been undertaken on the staff member’s FFP3 mask and that employees are aware of infection control standards and have undertaken appropriate training. Employers follow their own local policies and procedures on staff conduct issues on a case by case basis as they arise.
To ask Her Majesty's Government what steps they are taking to ensure medicines licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), through Oribis and the Innovative Licensing and Access Pathway (ILAP), are promptly reimbursed by the NHS.
To ask Her Majesty's Government what steps they are taking to ensure medicines licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), through Oribis and the Innovative Licensing and Access Pathway (ILAP), are promptly reimbursed by the NHS.
The National Institute for Health and Care Excellence (NICE) is committed to publishing draft guidance on new medicines at the time of licensing, with final guidance published within three months of licensing wherever possible. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are working together to ensure that there is an integrated, timely approach to supporting access for National Health Service patients to products licensed through Project Orbis and the Innovative Licensing and Access Pathway. Interim access arrangements may be considered where NICE’s guidance is not anticipated to be published in line with the three month timeframe.
To ask Her Majesty's Government how many planned discontinuation notices for the supply of medicines they have received as of 1 June 2021; and what steps they are taking to mitigate such notices.
To ask Her Majesty's Government how many planned discontinuation notices for the supply of medicines they have received as of 1 June 2021; and what steps they are taking to mitigate such notices.
We regularly receive notifications of discontinuations and possible discontinuations from suppliers, as well as information about shortages and potential shortages caused by a whole variety of reasons and numbers change daily. We are unable to provide this information as it is commercially sensitive.
The Department has well-established procedures to deal with medicines shortages and discontinuations and works with a range of stakeholders to ensure that the risks to patients are minimised when they do arise. Not all notifications will lead to the discontinuation of a medicine or a shortage in the market.
To ask Her Majesty's Government what plans they have (1) to increase the opportunity for pregnant women to have two doses of vaccinations by the time their pregnancy is full term by ensuring that that the NHS vaccination booking system allows them to book a second dose of vaccine eight...
To ask Her Majesty's Government what plans they have (1) to increase the opportunity for pregnant women to have two doses of vaccinations by the time their pregnancy is full term by ensuring that that the NHS vaccination booking system allows them to book a second dose of vaccine eight...
Appointments for a second dose of the vaccine have been brought forward from 12 to eight weeks for those in priority cohorts one to nine who are yet to receive their second dose. This is in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI), which the Government has accepted.
Pregnant women in priority cohorts one to nine due to age or clinical risk factor can book their second dose eight weeks after their first. Pregnant women in priority cohorts 10 to 12 can book their second dose 12 weeks after their first in line with their overall age cohort.
The National Booking Service operates according to the JCVI’s guidance on first and second doses. Local booking systems used by Primary Care Networks and general practitioner-led services have also been advised to operate according to this advice.
To ask Her Majesty's Government how many of the medical device innovations sent from the HealthTec Connect portal in its first 12 months to (1) NHS, and (2) Government, agencies, have since been adopted by NHS Supply Chain.
To ask Her Majesty's Government how many of the medical device innovations sent from the HealthTec Connect portal in its first 12 months to (1) NHS, and (2) Government, agencies, have since been adopted by NHS Supply Chain.
In the first 12 months of HealthTech Connect’s operation, 180 technologies were submitted, of which 142 were shared with NHS Supply Chain. None were selected.
NHS Supply Chain do not determine which products are appropriate for adoption by the National Health Service but may respond where products are selected by NHS England and NHS Improvement for adoption via routes such as MedTech Funding and the Accelerated Access Collaborative.
To ask Her Majesty's Government what plans they have (1) to put in place a framework agreement specifically for the adoption of medical devices innovation, and (2) to ensure that each procurement framework agreement has a section specifically for innovation adoption to speed up the use of innovative medical devices for...
To ask Her Majesty's Government what plans they have (1) to put in place a framework agreement specifically for the adoption of medical devices innovation, and (2) to ensure that each procurement framework agreement has a section specifically for innovation adoption to speed up the use of innovative medical devices for...
There are currently no plans for an additional framework agreement for medical device innovation. However, current frameworks do accommodate innovations from existing suppliers.
To ask Her Majesty's Government what assessment they have made of the value to taxpayers of over £4 million per annum being paid from NHS Trust budgets to cover the cost of NHS Providers.
To ask Her Majesty's Government what assessment they have made of the value to taxpayers of over £4 million per annum being paid from NHS Trust budgets to cover the cost of NHS Providers.
We have made no such assessment. It is for National Health Service trusts and foundation trusts to decide whether to join a representative body and whether it provides value for money.
To ask Her Majesty's Government, further to reports of shortages of tubular steel, what arrangements they plan to put in place to ensure that the NHS has enough supplies of rehabilitation equipment including (1) walking frames, (2) four-wheeled walkers, and (3) rollators.
To ask Her Majesty's Government, further to reports of shortages of tubular steel, what arrangements they plan to put in place to ensure that the NHS has enough supplies of rehabilitation equipment including (1) walking frames, (2) four-wheeled walkers, and (3) rollators.
Walking frames, four-wheeled walkers and rollators are largely made of tubular aluminium for lightweight purposes and therefore no impact of the reported steel shortages is expected.
Her Majesty's Government when the next stage of the NHS People Plan will be published.
Her Majesty's Government when the next stage of the NHS People Plan will be published.
In 2021-22 our focus is on supporting the immediate recovery of National Health Service staff and services. We are working with NHS England and NHS Improvement, Health Education England and systems and employers to determine our future workforce and people priorities. This will feed into the development of a longer term strategy, overseen by the National People Board.
To ask Her Majesty's Government what assessment they have made of the effect of the Protocol on Ireland/Northern Ireland on the availability of medicines and drugs in Northern Ireland.
To ask Her Majesty's Government what assessment they have made of the effect of the Protocol on Ireland/Northern Ireland on the availability of medicines and drugs in Northern Ireland.
We are continuing to engage with the European Union on the movement of medicines into Northern Ireland, as part of conversations regarding outstanding issues on the Protocol. Whilst these discussions are ongoing, we have not made a full assessment of the impact of the Protocol. However, we remain committed to maintaining the availability of medicines and drugs in Northern Ireland and actively monitor the situation.
To ask Her Majesty's Government what assessment they have made of the availability of new drugs and medicines in Northern Ireland under the separate licensing arrangements established by the Protocol on Ireland/Northern Ireland.
To ask Her Majesty's Government what assessment they have made of the availability of new drugs and medicines in Northern Ireland under the separate licensing arrangements established by the Protocol on Ireland/Northern Ireland.
We are continuing to engage with the European Union on the movement of medicines into Northern Ireland, as part of conversations regarding outstanding issues on the Protocol. Whilst these discussions are ongoing, we have not made a full assessment of the impact of the Protocol. However, we remain committed to maintaining the availability of medicines and drugs in Northern Ireland and actively monitor the situation.